Metropolitan Life Insurance CO Keros Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$2.27 Billion
Q1 2024

A detailed history of Metropolitan Life Insurance CO transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Metropolitan Life Insurance CO holds 1,353 shares of KROS stock, worth $61,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,353

Previous 1,424 4.99%

Holding current value

$61,832

Previous $56,000 58.93%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$41.26 - $70.48 $2,929 - $5,004	-71 Reduced 4.99%	1,353 $89,000
Q3 2023 Nov 14, 2023	BUY	$31.57 - $43.02 $6,061 - $8,259	192 Added 15.58%	1,424 $45,000
Q2 2023 Aug 10, 2023	BUY	$37.26 - $51.01 $7,079 - $9,691	190 Added 18.23%	1,232 $49,000
Q1 2023 May 15, 2023	SELL	$41.44 - $59.32 $6,174 - $8,838	-149 Reduced 12.51%	1,042 $44,000
Q4 2022 Jun 14, 2023	BUY	$39.45 - $51.77 $5,878 - $7,713	149 Added 14.3%	1,191 $57.2 Million

Q4 2022 Mar 30, 2023	BUY	$39.45 - $51.77 $4,260 - $5,591	108 Added 9.97%	1,191 $57,000
Q4 2022 Feb 15, 2023	BUY	$39.45 - $51.77 $4,260 - $5,591	108 Added 9.97%	1,191 $57,000
Q3 2022 Jun 14, 2023	BUY	$27.8 - $40.12 $1,139 - $1,644	41 Added 3.93%	1,083 $40.7 Million
Q2 2022 Jun 20, 2023	BUY	$26.03 - $67.04 $1,067 - $2,748	41 Added 3.93%	1,083 $29,000
Q1 2022 Jun 20, 2023	BUY	$42.12 - $59.36 $1,726 - $2,433	41 Added 3.93%	1,083 $58,000
Q1 2022 Mar 30, 2023	SELL	$42.12 - $59.36 $126,317 - $178,020	-2,999 Reduced 73.47%	1,083 $58,000
Q1 2022 May 12, 2022	SELL	$42.12 - $59.36 $126,317 - $178,020	-2,999 Reduced 73.47%	1,083 $59,000
Q4 2021 Jun 21, 2023	BUY	$36.95 - $62.89 $112,328 - $191,185	3,040 Added 291.75%	4,082 $238,000
Q3 2021 Jun 21, 2023	BUY	$29.27 - $43.71 $88,980 - $132,878	3,040 Added 291.75%	4,082 $161,000
Q2 2021 Jun 21, 2023	BUY	$42.4 - $70.11 $128,896 - $213,134	3,040 Added 291.75%	4,082 $173,000
Q2 2021 Mar 30, 2023	BUY	$42.4 - $70.11 $11,448 - $18,929	270 Added 7.08%	4,082 $173,000
Q2 2021 Aug 16, 2021	BUY	$42.4 - $70.11 $172,907 - $285,908	4,078 Added 101950.0%	4,082 $173,000
Q1 2021 Jun 26, 2023	BUY	$54.0 - $75.28 $149,580 - $208,525	2,770 Added 265.83%	3,812 $235 Million
Q1 2021 May 14, 2021	SELL	$54.0 - $75.28 $205,632 - $286,666	-3,808 Reduced 99.9%	4 $235,000
Q4 2020 Jun 22, 2023	BUY	$36.0 - $82.74 $99,720 - $229,189	2,770 Added 265.83%	3,812 $268,000
Q4 2020 Mar 30, 2023	BUY	$36.0 - $82.74 $42,516 - $97,715	1,181 Added 44.89%	3,812 $268,000
Q4 2020 Feb 16, 2021	BUY	$36.0 - $82.74 $42,516 - $97,715	1,181 Added 44.89%	3,812 $269,000
Q3 2020 Jun 26, 2023	BUY	$27.04 - $62.21 $42,966 - $98,851	1,589 Added 152.5%	2,631 $101,000
Q2 2020 Jun 26, 2023	BUY	$20.08 - $40.39 $31,907 - $64,179	1,589 Added 152.5%	2,631 $98,000
Q2 2020 Mar 30, 2023	BUY	$20.08 - $40.39 $28,915 - $58,161	1,440 Added 120.91%	2,631 $98,000
Q2 2020 Aug 14, 2020	BUY	$20.08 - $40.39 $52,830 - $106,266	2,631 New	2,631 $99,000

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account

Metropolitan Life Insurance CO Keros Therapeutics, Inc. Transaction History